Last edition
News about Global Pharma
Ono Pharma Seeks Expanded OPDIVO Use for Anaplastic Thyroid Cancer in Japan
Ono Pharma seeks expanded approval for OPDIVO in Japan for unresectable anaplastic thyroid cancer after a trial with Lenvima met its primary endpoint.
Global Pharma | 12/06/2026 | By News Bureau
EMA Confirms Asundexian MAA for Assessment in Secondary Prevention of Ischemic Stroke
The EMA has accepted the Marketing Authorisation Application (MAA) for asundexian, the first Factor XIa (FXIa) inhibitor under review in Europe for secondary prevention of ischemic stroke. The submission is supported by positive phase 3 OCEANIC-STROKE data.
Global Pharma | 11/06/2026 | By News Bureau | 111
NIH Identifies Cells that Protect against Inflammatory Bowel Disease
The National Institutes of Health (NIH) researchers have identified regulatory cells that help protect against Inflammatory Bowel Disease (IBD), a discovery that could lead to improved diagnosis, treatment, and disease management strategies.
Global Pharma | 10/06/2026 | By News Bureau
WuXi Biologics Completes Topping-Out of Singapore Drug Product Facility
WuXi Biologics has completed the modular topping-out of its Singapore CRDMO hub drug product facility, a key manufacturing site designed to meet stringent standards. Once operational, the facility is expected to produce approximately 100 million pre-filled syringes and vials annually.
Global Pharma | 06/06/2026 | By News Bureau
J&J Introduces VARIPULSE Platform for Atrial Fibrillation Treatment in India
Johnson & Johnson has launched the VARIPULSE platform in India, introducing Pulsed Field Ablation (PFA) technology for catheter ablation procedures in patients with atrial fibrillation (AFib).
Global Pharma | 04/06/2026 | By News Bureau
Aptar Pharma Files Patents, Reports Positive Preclinical Data for GLP-1 Nasal and Pulmonary Delivery
Aptar Pharma announced new patent applications and positive preclinical data supporting intranasal and pulmonary GLP-1 delivery, expanding its capabilities in inhaled and intranasal biologic drug delivery.
Global Pharma | 29/05/2026 | By News Bureau
Eli Lilly and Company reports that a single dose of investigational gene-editing therapy VERVE-102 delivered sustained reductions in PCSK9 and LDL cholesterol for up to 18 months in high-risk cardiovascular patients.
Global Pharma | 26/05/2026 | By News Bureau | 295
AbbVie Receives Positive CHMP Opinion for MAVIRET in Acute Hepatitis C Treatment
AbbVie receives a positive CHMP opinion for MAVIRET to treat acute hepatitis C, supported by Phase 3 data demonstrating safety and efficacy in adults with acute HCV infection.
Global Pharma | 26/05/2026 | By News Bureau | 111
Venus Remedies Secures Saudi FDA Approval for Plerixafor Oncology Therapy
Venus Remedies receives Saudi FDA approval for Plerixafor, marking its first global marketing authorisation for the specialty oncology therapy used in stem cell mobilisation for multiple myeloma and non-Hodgkin lymphoma patients undergoing autologous transplantation.
Global Pharma | 25/05/2026 | By News Bureau | 120
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Global Pharma | 22/05/2026 | By News Bureau | 431
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy